Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This randomized phase I trial is studying the side effects and best dose of Bowman-Birk inhibitor concentrate in preventing cancer in healthy men. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of Bowman-Birk inhibitor concentrate may prevent cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Unspecified Adult Solid Tumor, Protocol Specific |
Other: placebo Drug: Bowman-Birk inhibitor concentrate |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Prevention |
| Official Title: | Phase I Single Dose Safety and Pharmacokinetic Study of Bowman Birk Inhibitor Concentrate, Delivered as an Orange Juice Suspension to Healthy Male Volunteers Between 18 and 65 Years of Age |
- Safety as measured by NCI Common Toxicity Criteria and a recommended Phase II dose (RPTD) [ Time Frame: Up to 4 weeks ] [ Designated as safety issue: Yes ]
- Pharmacokinetics measurements of BBI in the blood and urine [ Time Frame: 0 (immediately prior to BBIC administration), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 hours after BBIC administration ] [ Designated as safety issue: No ]Mean, median and 95% confidence interval will then be calculated for each parameter for each dose group. The relationship between dose and the above parameters will be investigated using simple linear regression.
| Estimated Enrollment: | 20 |
| Study Start Date: | January 2006 |
| Primary Completion Date: | April 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Arm I (Bowman-Birk inhibitor concentrate)
Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
|
Drug: Bowman-Birk inhibitor concentrate
Given orally
Other Name: BBIC
|
|
Placebo Comparator: Arm II (placebo)
Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
|
Other: placebo
Given orally
Other Name: PLCB
|
Detailed Description:
PRIMARY OBJECTIVES:
I. Determine the toxic effects of Bowman-Birk inhibitor concentrate, administered as an orange juice suspension, in healthy male participants.
II. Determine a safe dose range of this drug in these participants. III. Determine a recommended phase II dose of this drug in these participants.
SECONDARY OBJECTIVES:
I. Determine the pharmacokinetics of this drug in these participants.
OUTLINE: This is a randomized, placebo-controlled, double-blind, dose-escalation study.
Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
After completion of study treatment, participants are followed periodically for 4 weeks.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy volunteer
- Male
- Performance status - ECOG 0-2
- RBC normal
- WBC ≥ 3,000/mm^3
- Platelet count normal
- Hemoglobin normal
- Hematocrit normal
- ALT and AST normal
- Bilirubin normal
- Creatinine normal
- No history of heart disease
- EKG normal
- No history of pancreatitis or obstruction of pancreatic ducts
- No history of pancreatic cancer or pancreatic adenoma
- Amylase normal
- Lipase normal
- Cholesterol normal
- Triglycerides normal
- Serum glucose ± 10% of normal
- Within 15% of ideal body weight
- No history of chronic medical condition
- No history of excessive alcohol consumption (i.e., > 2 alcoholic beverages per day on average)
- No history of amyloidosis
Non-smoker
- Former smokers are eligible provided they have not smoked within the past 3 months
- No history of medical condition that would influence gastrointestinal uptake of the study drug
- No history of diabetes mellitus
- No allergy or prior adverse reaction to soybeans
- Not a vegetarian
- No diagnosis of cancer within the past 5 years except nonmelanoma skin cancer
- No evidence of other life-threatening disease
- No evidence of psychiatric problems
- More than 12 months since prior chemotherapy
- More than 1 month since prior experimental drugs
- More than 3 days since prior consumption of alcoholic beverages
- More than 2 weeks since prior and no concurrent regular use (i.e., > 3 times/week) of nonsteroidal anti-inflammatory drugs
- More than 2 weeks since prior multivitamin tablets (or other vitamin supplements) of > 2 per day
- No more than 2 multivitamin tablets (or other vitamin supplements) per day during study participation
- No more than 1 serving of tofu, soy milk, or other primarily soy-based food per day
Contacts and Locations| United States, Pennsylvania | |
| Abramson Cancer Center of The University of Pennsylvania | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Principal Investigator: | Robert Lustig | Abramson Cancer Center of the University of Pennsylvania |
More Information
No publications provided
| Responsible Party: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00287833 History of Changes |
| Other Study ID Numbers: | NCI-2011-01479, UPCC-706366, N01-CN-25118, CDR0000429594 |
| Study First Received: | February 6, 2006 |
| Last Updated: | May 1, 2013 |
| Health Authority: | United States: Food and Drug Administration |
ClinicalTrials.gov processed this record on May 21, 2013